USPTO Patents Application 10551504

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

A. CLASSIFICATION OF SUBIECT MATTER

A61K45/00 {2006 . 01) i , A61 K39/395 ( 2 0 0 6 . 0 1 ) i , A61 P 7/0 6 ( 2 0 0 6 . 0 1 ) i , A61P35/02
(2006. 01) i, (2006 . 01) i

According to International Patent Classification (IPC) or to both national classification and IPC
B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K45/00, A61K39/395, A61P7/06, A61P35/02, A61P43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2007

Kokai Jitsuyo Shinan Koho 1971-2007 Toroku Jitsuyo Shinan Koho 1994-2007

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BIOSIS (STN) , CAplus(STN), EMBASE(STN), MEDLINE (STN) , WPI (DIALOG) ,
JMEDPlus ( JDream2 ) , JST75 80 ( JDream2 ) , JSTPlus ( JDream2 )

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

X

X

JP 10-510842 A (ZymoGenetics, Inc.),

20 October, 1998 (20.10.98),

Claims; page 8, lines 21 to 24; examples

& WO 96/40218 Al & AU 199662500 A

& EP 831888 Al & US 6013067 A

& MX 199709244 Al & KR 1999022420 A

& CN 1190348 A

JP 2005-539082 A (Ortho-Mcneil Pharmaceutical
inc . ) ,

22 December, 2005 (22.12.05),

1-11, 18, 19,
21-23

1-11, 18-20,

22,23

Full

text

& WO

2004/026332 Al

&

AU

2003275077 Al

& EP

1542714 Al

&

NO

200501841 A

& BR

200314591 A

&

US

2005/0282277 Al

& CN

1723036 A

&

ZA

200503036 A

& KR

2005093759 A

I x I Furtlier documents are listed in the continuation of Box C.

I I See patent family annex.

"E"

"L"

"O"

Special categories of cited documents: '"p"
document defining the general state of the art which is not considered to
be of particular relevance

earlier application or patent but published on or after the international filing "X"
date

document which may throw doubts on priority claim(s) or which is

cited to establish the publication date of another citation or other "y"

special reason (as specified)

document referring to an oral disclosure, use, exhibition or other means

document published prior to the international filing date but later than the
priority date claimed "&"

later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention

document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone

document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

document member of the same patent family

Date of the actual completion of the international search
24 July, 2007 (24.07.07)

Date of mailing of the international search report

07 August, 2007 (07.08.07)

Name and mailing address of the ISA/

Japanese Patent Office

Facsimile No.

Authorized officer
Telephone No.

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2 00 7/0618 50

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*

Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

X
Y

X
Y

NAKAMURA, T . , et a.1 . , A Novel Non-Peptidyl Human
C-Mpl Agonist, NIP- 004, Stimulates Human
Megakaryopoiesis and Thrombopoiesis [online] .
Blood (ASH Annual Meeting Abstracts), 2005, 106:
Abstract 3148. Retrieved from the Internet:
<URL : http : //abstracts . hematology library . org/ cgi/
content / abstract / ashratg ; 10 6/ 1 1/3 14 8?maxtoshow=&
HITS=10&hitS=10&RESULTFORMAT=&fulltext=NIP-0 04&
searchid=l&FlRSTlNDEX=0&volume=106&issue=ll&
resourcetype=HWClT> , full text

l , 18
2-11, 19-23

SUZUKI , K. ,
Thrombopo i e
(ASH Annual
Abstract 22
<URL:http: /
content / abs
HITS=10&hit
searchid=l&
resourcetyp

et al., YM477, a Novel Orally-Active
tin Receptor Agonist [online] . Blood

Meeting Abstracts), 2005, 106:
98. Retrieved from the Internet:
/ abstracts . hematology library . org/ cgi/
tract/ashmtg; 106/1 1/22 98?maxtoshow=&
S=10&RESULTFORMAT=&f ulltext=YM4 77&
FlRSTlNDEX=0&volume=106&issue=ll&
e=HWClT>, full text

1 , 18
2-11, 19-23

WO 2005/107784 Al
Ltd. ) ,

17 November, 2 0 05
Claims; abstract
(Family: none)

(Chugai Pharmaceutical Co.
(17.11.05) ,

1-11, 18-23

WO 2005/056604 Al (Chugai Pharmaceutical Co.
Ltd . ) ,

2 3 June , 2005 (23.06.05),
Claims; abstract

& EP 1616881 Al & NO 200603224 A

& US 2006/0222643 Al & AU 2004297111 Al

& MX 2006006289 Al & BR 200417077 A

& KR 2006107572 A

WO 02/33072 Al (Chugai Pharmaceutical Co.,
Ltd . ) ,

25 April, 2002 (25.04.02),
Claims; abstract
& AU 200210917 A &
& KR 2003055274 A &

1-11, 18-23

1-11, 18-23

EP 1327680 Al
CN 1469925 A

& US 2004/0091475 Al

& CN 1721445 A

JP 2004-222502 A (Asahi Kasei Corp.),
12 August, 2004 (12.08.04),
(Family: none)

JP 2005-204539 A (Mitsubishi Pharma Corp.),
04 August, 2005 (04.08.05),
& WO 2005/071064 Al

1-11, 18-23

1-11, 18-23

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

L [3 Claims Nos.: 12-17

because they relate to subject matter not required to be searched by this Authority, namely:
The invention according to claims 12-17 includes the step of administering
an agonist for TPO receptor to a test subject, and corresponds to a method
for treatment of the human body by therapy because the human is included
in the test subject. (PCT Article 17(2)(a)(i), PCT Rule 39.1(iv))

Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an
extent that no meaningful international search can be carried out, specifically:

3. □

Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. Ill Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

2- □

3- D

As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.

As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of
any additional fee.

As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:

4- □

No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest I I The additional search fees were accompanied by the applicant's protest and, where applicable,

the payment of a protest fee..

The additional search fees were accompanied by the applicant's protest but the applicable protest
fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

Regarding claims 1-11, 18-23

Claims 1-11, 18-23 describe an agonist for TPO receptor as an active
ingredient of a drug or an ingredient to be used for manufacturing a
drug .

As the agonist for TPO receptor, a lot of compounds other than TPO
can be included, however, even a person skilled in the art cannot clearly
realize the whole compounds. Further, even if the description of the
specification is examined, it is not described to such an extent that
the whole compounds are made clear.

Thus, a sufficient support by the specification is not made by the
description of the claims . Further, it is not clearly and sufficiently
disclosed to such an extent that a person skilled in the art can make
implementation. (PCT Articles 5 and 6)

Incidentally, in the creation of this international search report,
a prior art search was carried out based on the description of the
specification within a reasonable range.

Form PCT/ISA/210 (extra sheet) (April 2005)